ASTH · Astrana Health Inc.

Current Thesis

Astrana is a risk-bearing physician platform whose revenue growth is now being converted into profit faster than the top line is growing. On 2026-08-06 the company reported Q2 revenue of $972.5M, up 49% from $654.8M a year earlier, with adjusted EBITDA of $68.9M (+43%) and adjusted diluted EPS of $0.80 (+45%). It raised the FY2026 adjusted EBITDA range to $255–280M while leaving the revenue range untouched at $3.800–4.100B. That is the leg an investor is buying: a full-risk mix shift that lifts margin without needing the revenue line to beat.

The complication is that the revenue line did not beat. Q2 revenue came in below the $985.716M consensus (Benzinga, 2026-08-06), and the Q3 guide of $1.000–1.030B straddles rather than clears the $1.021B consensus. Truist raised its target to $55 on 2026-08-11 and Barclays to $53 on 2026-08-07; neither produced a trend. At the 2026-09-04 close of $38.47 the shares sit 22.8% below the $49.81 52-week high with RSI(14) at 41.5 and a three-month price change of +0.2%.

On where the story sits: the narrative is maturing — the full-risk value-based-care frame is well understood by the specialist sell side, both post-print target raises landed inside five sessions of the 2026-08-06 report, and the flow behind them has not widened the tape since, with the name flat over three months and no company-dated event on the calendar between 2026-09-05 and the Q3 print.

Bullish and bearish views on Astrana Health Inc.

The model's bull view on Astrana Health Inc. (ASTH), in brief: Margin raise without a revenue raise (2026-08-06). The bear view: The top line keeps landing short of the Street. Both cases follow in full.

Bull Case

• Margin raise without a revenue raise (2026-08-06). FY2026 adjusted EBITDA guidance lifted to $255–280M; revenue reaffirmed at $3.800–4.100B; free cash flow reaffirmed at $105–132.5M. The upgrade came entirely on the profit line.
• Q2 unit economics (2026-08-06). Revenue $972.5M, +49% YoY from $654.8M. Adjusted EBITDA $68.9M vs $48.1M. Adjusted diluted EPS $0.80 vs $0.55. GAAP diluted EPS $0.40 against a $0.34 consensus (Benzinga, 2026-08-06), up from $0.19.
• Cash conversion is arriving early in the year. First-half 2026 operating cash flow $100.8M and free cash flow $92.9M, against a full-year FCF guide of $105–132.5M — most of the year's guided cash was already generated by 2026-06-30.
• The sequential step-up is guided. Q3 adjusted EBITDA guidance of $72.5–77.5M sits above the $68.9M just delivered.
• Mix shift is the mechanism. Coverage of the Q2 investor deck put full-risk arrangements at 81% of capitation revenue versus 76% a year earlier (Investing.com summary of the 2026-08-06 deck).
• Value-based execution has a dated receipt. On 2026-07-13 the company disclosed its ACOs delivered $120.4M in gross shared savings for the 2024 performance year.
• Scale. More than 20,000 providers and approximately 1.5 million patients in value-based arrangements as of the Q2 release.

Bear Case

• The top line keeps landing short of the Street. Q2 revenue $972.5M vs $985.716M consensus; the FY range of $3.800–4.100B brackets a $4.001B consensus rather than exceeding it (Benzinga, 2026-08-06). A compounder narrative that misses revenue gets re-rated on the multiple even while EBITDA rises.
• Full risk cuts both ways. With the majority of capitation revenue in full-risk form, medical cost trend is absorbed directly. Utilization surprises in Medicare Advantage have repeatedly been the sector's failure mode, and they surface inside a single quarter.
• The platform carries debt. At 2026-06-30: cash and equivalents $400.8M, long-term debt net of $882.7M, total assets $2,282.1M. Growth has been financed, and the Prospect Health synergies cited on the Q2 call are integration-dependent.
• The two target raises did nothing. Truist $55 (2026-08-11) and Barclays $53 (2026-08-07) were followed by a tape that is flat over three months and 22.8% below its high. Published targets that far above the 2026-09-04 close of $38.47 have not attracted a bid that widened.
• Nothing dated in the window. The IR press-release feed shows no release after 2026-08-06 as of 2026-09-05, and no September conference appearance has been announced. The next company-controlled information event is the Q3 print, roughly two months out.

Setup & Price Structure

The 2026-09-04 close of $38.47 is 22.8% under the $49.81 52-week high, with RSI(14) at 41.5 — mid-range momentum, no extension. The three-month price change of +0.2% means the entire post-print move has round-tripped inside a range.

There is a recovery leg underneath the current level: Simply Wall St records a 2026-09-02 close of $38.57, up 11.75% over the trailing month and 23.75% over 52 weeks. Read together with the flat three-month change, the shape is a drawdown into early August followed by a partial recovery that has stalled just under $39. The structure that matters is the base of that recovery leg; losing it returns the name to post-print lows.

Crowding and positioning observables, stated as observables:

• Price sits below its 52-week high — the distance-above-a-rising-average crowding signature is absent at $38.47, and RSI(14) at 41.5 is in the lower half of its range.
• Two sell-side target raises clustered within five sessions (2026-08-07, 2026-08-11); no further published revision has surfaced in the three weeks since.
• Insider filings surfaced for 2026 are tax-withholding dispositions rather than open-market sales
• A dated share-supply event exists: the CEO's 201,056-RSU grant begins vesting in eight equal semi-annual installments on 2026-10-06, starting a recurring withholding cadence from that date.
• No earnings date falls inside the next 30 days, so the near-term tape has no scheduled binary to price.

Catalyst Calendar (next 30 days)

• 2026-10-06 — First of eight semi-annual vesting installments on the CEO's 201,056-RSU grant. Mechanical, but it begins a recurring Form 4 cadence that screeners will render as insider selling.
• ~2026-10-15 (est.) — Medicare Advantage annual enrollment period opens on the standard CMS window. Membership commentary for 2027 begins forming here; a sector-level input, not a company release.
• ~2026-11-05 (est.) — Q3 2026 results, unscheduled as of 2026-09-05. Graded against the guide of $1.000–1.030B revenue and $72.5–77.5M adjusted EBITDA, and against whether the FY adjusted EBITDA range of $255–280M moves again.
• No company-announced event between 2026-09-05 and 2026-10-05. The press-release feed ends at 2026-08-06.

What Would Change Our Mind

The read rests on three things: the EBITDA guide keeps moving up while revenue holds, the recovery leg off the early-August drawdown holds, and full-risk economics stay clean. Each has a break condition.

• Structure. A weekly close below $34 erases the recovery leg implied by the +11.75% trailing-month move into the 2026-09-02 close of $38.57 and returns the shares to post-print lows; at that point the 2026-08-06 guidance raise has been fully faded by the tape.
• Fundamental. Q3 revenue printing below the $1.000B low end of the guide, or any trim to the $255–280M FY adjusted EBITDA range, removes the specific thing that was raised on 2026-08-06.
• Cost trend. Medical-cost-ratio deterioration disclosed on the Q3 call, or a large Medicare Advantage payer guiding utilization higher, converts the full-risk mix from a margin argument into a liability.
• Catalyst decay. If the Q3 print passes without a guidance raise, the cadence of raising into every print — the support under the published $53–55 targets — is gone, and the story turns saturated with no new bid to absorb it.

Correlation Notes

No theme cluster in the registry carries this name as of 2026-09-05, so nothing in the thesis depends on a group move; this is a single-name execution setup and should be graded as one.

The practical correlation channel is inferred rather than measured: as an entity whose economics are set by Medicare Advantage benchmarks and realized utilization, the name tends to move on medical-cost-trend headlines out of the large MA payers and on CMS rate policy, neither of which the company controls. The next scheduled policy input of that kind — the CY2028 advance notice — falls well outside this window, in roughly Q1 2027.

The second channel is deal-specific: Prospect Health synergies were named on the 2026-08-06 call as a driver of the EBITDA beat, tying a portion of the margin story to a single acquisition rather than to the sector.